)
Edge29 May 2026
Who You Gonna Call? The Story of Rollins
How Rollins built one of America's most consistent businesses through recurring pest control, trusted local brands, and decades of acquisitions.
Satellos Bioscience
Satellos Bioscience (MSCL) investor relations material
Satellos Bioscience Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary15 May, 2026
Executive summary
Eleven clinical trial sites for BASECAMP are active, with full enrollment expected in Q3 2026.
TRAILHEAD Phase 2 study in adults with DMD initiated in the U.S., targeting ages 16–25.
$57M raised in Q1 2026, supporting operations through 2027 and enabling Nasdaq uplisting.
Financial highlights
Cash and equivalents totaled $69.9M as of March 31, 2026, up from $27.7M at year-end 2025, mainly due to an equity offering.
Net loss for Q1 2026 was $9.8M ($0.53/share), compared to $6.1M ($0.44/share) in Q1 2025.
R&D expenses rose to $7.3M from $4.5M year-over-year, driven by clinical trial costs.
G&A expenses increased to $2.7M from $1.9M year-over-year, reflecting higher headcount and Nasdaq listing costs.
Outlook and guidance
BASECAMP enrollment completion is on track for Q3 2026, with additional sites to be activated in Q2.
TRAILHEAD aims to enroll up to 30 adults with DMD in the U.S. and Australia, with updates expected throughout 2026.
Current cash runway extends through 2027, supporting all planned milestones.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Satellos Bioscience
- Advancing oral DMD therapy with strong cash reserves and Phase 2 trial planned for late 2025.MSCL
Registration filing3 Jun 2026 - SAT-3247 delivers sustained, clinically meaningful muscle strength gains in DMD patients.MSCLInvestor presentation2 Jun 2026
- Advanced SAT-3247 with positive DMD data, regulatory milestones, and Phase 1 trial preparations.MSCLQ2 20242 Jun 2026
- Clinical trial progress and strong preclinical results drive R&D spending and regulatory momentum.MSCLQ3 20242 Jun 2026
- SAT-3247 advanced in clinical trials with strong safety data and a robust cash position for 2026.MSCLQ4 20242 Jun 2026
- Phase 1b DMD trial completed enrollment; $41.2M cash supports Phase 2 plans.MSCLQ1 20252 Jun 2026
- Advanced SAT-3247 clinical trials and board expertise, with improved net loss and strong cash position.MSCLQ3 20252 Jun 2026
- Phase 1b data showed safety and doubled grip strength in DMD; cash at $38.2M USD.MSCLQ2 20252 Jun 2026
- Advanced SAT-3247 clinical trials and secured $57.2M financing, extending cash runway through 2027.MSCLQ4 20252 Jun 2026
Next Satellos Bioscience earnings date
Jefferies Global Healthcare Conference 20264 Jun, 2026
Satellos Bioscience
Next Satellos Bioscience earnings date
Jefferies Global Healthcare Conference 20264 Jun, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage